PT3348264T - Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular - Google Patents

Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular

Info

Publication number
PT3348264T
PT3348264T PT181601741T PT18160174T PT3348264T PT 3348264 T PT3348264 T PT 3348264T PT 181601741 T PT181601741 T PT 181601741T PT 18160174 T PT18160174 T PT 18160174T PT 3348264 T PT3348264 T PT 3348264T
Authority
PT
Portugal
Prior art keywords
imidazol
methylphenyl
drugs
methanol
ethyl
Prior art date
Application number
PT181601741T
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44675870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3348264(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT3348264T publication Critical patent/PT3348264T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT181601741T 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular PT3348264T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38337010P 2010-09-16 2010-09-16

Publications (1)

Publication Number Publication Date
PT3348264T true PT3348264T (pt) 2020-04-02

Family

ID=44675870

Family Applications (7)

Application Number Title Priority Date Filing Date
PT16161922T PT3053576T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para redução da pressão intraocular
PT16161920T PT3050563T (pt) 2010-09-16 2011-09-16 Pró-fármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para o tratamento de doenças e afeções da pele
PT161619234T PT3050564T (pt) 2010-09-16 2011-09-16 Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
PT117609628T PT2616068T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular
PT181601741T PT3348264T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular
PT117609636T PT2616069T (pt) 2010-09-16 2011-09-16 Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
PT181571472T PT3338777T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4- il)etil)-2-metilfenil]metanol para tratamento de doenças retinianas

Family Applications Before (4)

Application Number Title Priority Date Filing Date
PT16161922T PT3053576T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para redução da pressão intraocular
PT16161920T PT3050563T (pt) 2010-09-16 2011-09-16 Pró-fármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para o tratamento de doenças e afeções da pele
PT161619234T PT3050564T (pt) 2010-09-16 2011-09-16 Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
PT117609628T PT2616068T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol para abaixamento da pressão intraocular

Family Applications After (2)

Application Number Title Priority Date Filing Date
PT117609636T PT2616069T (pt) 2010-09-16 2011-09-16 Pró-fármacos éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil]metanol
PT181571472T PT3338777T (pt) 2010-09-16 2011-09-16 Pró-fármacos ésteres de [3-(1-(1h-imidazol-4- il)etil)-2-metilfenil]metanol para tratamento de doenças retinianas

Country Status (29)

Country Link
US (9) US8653123B2 (pt)
EP (13) EP3698789A1 (pt)
JP (4) JP2013541527A (pt)
KR (7) KR101840500B1 (pt)
CN (5) CN105412092B (pt)
AR (4) AR083017A1 (pt)
AU (4) AU2011301901B2 (pt)
BR (4) BR112013006362A2 (pt)
CA (8) CA3077732A1 (pt)
CL (4) CL2013000734A1 (pt)
CY (3) CY1121024T1 (pt)
DK (9) DK3078376T3 (pt)
ES (10) ES2788051T3 (pt)
HK (5) HK1185541A1 (pt)
HU (5) HUE049573T2 (pt)
IL (4) IL225278A (pt)
MX (4) MX2013003008A (pt)
MY (4) MY191369A (pt)
NZ (1) NZ608751A (pt)
PL (7) PL3053576T3 (pt)
PT (7) PT3053576T (pt)
RU (4) RU2013116763A (pt)
SG (4) SG188570A1 (pt)
SI (5) SI3050563T1 (pt)
TR (1) TR201909249T4 (pt)
TW (4) TW201240661A (pt)
UA (1) UA112973C2 (pt)
WO (4) WO2012037453A1 (pt)
ZA (4) ZA201302194B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2880578T3 (es) 2009-02-13 2021-11-24 Allergan Inc Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases
EP2734200A1 (en) * 2011-07-22 2014-05-28 Allergan, Inc. Alpha-2 adrenergic modulators for treating visual disorders mediated by central visual projections from the eye
AU2012340806B2 (en) 2011-11-21 2017-10-19 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3H-imidazole derivatives for treating retinal diseases
USD794650S1 (en) 2014-11-28 2017-08-15 Samsung Electronics Co., Ltd. Display screen or portion thereof with a graphical user interface
CN108310442B (zh) * 2017-01-17 2021-08-27 台北科技大学 眼科用组合物
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
CN108872431B (zh) * 2018-07-09 2021-03-23 成都倍特药业股份有限公司 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法
CN112552314B (zh) * 2018-08-24 2022-03-04 杭州阿诺生物医药科技有限公司 Sting激动剂小分子抗肿瘤化合物及其应用
BR112023021140A2 (pt) * 2021-04-16 2023-12-12 Ads Therapeutics Llc Cofármaco compreendendo uma fração de agonista muscarínico e uma fração de agonista alfa2 adrenérgico, ou um sal farmacêutico deste, composição farmacêutica e formulação farmacêutica

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE147619T1 (de) 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5459133A (en) * 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0729459B1 (en) 1993-11-15 2003-03-12 Schering Corporation Phenyl-alkyl imidazoles as h3-receptor antagonists
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
WO2004106307A2 (fr) * 2003-05-27 2004-12-09 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Nouveaux derives d’imidazoles, leur preparation et leur utilisation en tant que medicament
JP2007528020A (ja) * 2003-07-14 2007-10-04 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 投影装置
BRPI0414277A (pt) * 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
MXPA06013649A (es) 2004-05-25 2007-07-09 Sansrosa Pharmaceutical Dev In Compuestos, formulaciones, y metodos para tratar o prevenir desordenes inflamatorios de la piel.
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
AU2005290075A1 (en) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7902247B2 (en) 2008-01-09 2011-03-08 Allergan, Inc. Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors
WO2010091209A1 (en) 2009-02-06 2010-08-12 Allergan, Inc. Pyridine compounds as subtype selective modulators of alpha2b and/or alpha 2c adrenergic receptors
ES2880578T3 (es) 2009-02-13 2021-11-24 Allergan Inc Composiciones farmacéuticas que comprenden (3-(1-(1H-imidazol-4-il)etil)-2-metilfenil)metanol
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8653123B2 (en) * 2010-09-16 2014-02-18 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating retinal diseases

Also Published As

Publication number Publication date
DK2616068T3 (en) 2016-08-29
US20120136036A1 (en) 2012-05-31
HUE038698T2 (hu) 2018-11-28
CA2812197A1 (en) 2012-03-22
EP3050563B1 (en) 2018-05-09
EP2616068B1 (en) 2016-07-13
HK1185540A1 (zh) 2014-02-21
EP3078376B1 (en) 2019-03-27
WO2012037453A1 (en) 2012-03-22
BR112013006352A2 (pt) 2016-06-28
DK2616069T3 (en) 2016-12-19
PL3050564T3 (pl) 2020-06-01
HK1185541A1 (zh) 2014-02-21
CY1122958T1 (el) 2021-10-29
PT3338777T (pt) 2020-05-06
KR20200091507A (ko) 2020-07-30
US8492422B2 (en) 2013-07-23
NZ608751A (en) 2015-04-24
TWI591058B (zh) 2017-07-11
JP2013537236A (ja) 2013-09-30
AU2011301856C1 (en) 2016-09-08
US8501796B2 (en) 2013-08-06
AU2011301847B2 (en) 2016-02-11
KR20140003407A (ko) 2014-01-09
MY173846A (en) 2020-02-24
PL3348264T3 (pl) 2020-08-24
HK1185538A1 (zh) 2014-02-21
SI3050564T1 (sl) 2020-02-28
MX2013003009A (es) 2013-06-28
EP2616069B1 (en) 2016-11-16
AR083019A1 (es) 2013-01-23
SG188573A1 (en) 2013-04-30
US20160354346A1 (en) 2016-12-08
CN105412092A (zh) 2016-03-23
PL3338777T3 (pl) 2020-07-13
AR083017A1 (es) 2013-01-23
BR112013006362A2 (pt) 2016-06-28
EP3053576A1 (en) 2016-08-10
KR101840500B1 (ko) 2018-03-20
EP3050564A1 (en) 2016-08-03
EP3348264B1 (en) 2020-01-01
CN105412092B (zh) 2020-11-17
KR102354097B1 (ko) 2022-01-20
MX2013003008A (es) 2013-06-28
SI3338777T1 (sl) 2020-08-31
AU2011301847A1 (en) 2013-05-02
KR20130114140A (ko) 2013-10-16
ES2904479T3 (es) 2022-04-05
PL2616069T3 (pl) 2017-04-28
CN103221045A (zh) 2013-07-24
AU2011301932C1 (en) 2016-09-01
RU2612351C2 (ru) 2017-03-07
RU2013116403A (ru) 2014-10-27
CA2811559A1 (en) 2012-03-22
AR083020A1 (es) 2013-01-23
DK3053576T3 (en) 2018-08-20
TW201305116A (zh) 2013-02-01
CL2013000736A1 (es) 2013-07-12
TW201240662A (en) 2012-10-16
TR201909249T4 (tr) 2019-07-22
EP2616069A1 (en) 2013-07-24
SI3050563T1 (sl) 2018-10-30
ES2788051T3 (es) 2020-10-20
JP6045495B2 (ja) 2016-12-14
US20140057958A1 (en) 2014-02-27
RU2013116541A (ru) 2014-10-27
SG188572A1 (en) 2013-04-30
KR20130105658A (ko) 2013-09-25
RU2013116763A (ru) 2014-10-27
UA112973C2 (uk) 2016-11-25
JP6073229B2 (ja) 2017-02-01
CA3122745A1 (en) 2012-03-22
CY1122809T1 (el) 2021-05-05
PT2616068T (pt) 2016-09-13
PL2616068T3 (pl) 2016-11-30
TW201305117A (zh) 2013-02-01
ES2607084T3 (es) 2017-03-29
ES2760920T3 (es) 2020-05-18
SG188570A1 (en) 2013-04-30
KR101840501B1 (ko) 2018-05-04
WO2012037484A1 (en) 2012-03-22
DK3050563T3 (en) 2018-08-13
AU2011301901A1 (en) 2013-05-02
CN103200941A (zh) 2013-07-10
CL2013000734A1 (es) 2013-11-08
AU2011301932B2 (en) 2016-02-25
WO2012037499A1 (en) 2012-03-22
EP3338777A1 (en) 2018-06-27
EP3078376A1 (en) 2016-10-12
JP2013541527A (ja) 2013-11-14
CL2013000733A1 (es) 2013-08-23
CA3116249A1 (en) 2012-03-22
JP2013540749A (ja) 2013-11-07
MY191369A (en) 2022-06-20
EP2616068A1 (en) 2013-07-24
BR112013006320B1 (pt) 2022-08-30
US20150148394A1 (en) 2015-05-28
EP3050563A1 (en) 2016-08-03
AR083018A1 (es) 2013-01-23
PL3053576T3 (pl) 2018-11-30
ES2684055T3 (es) 2018-10-01
CN103200942A (zh) 2013-07-10
WO2012037490A1 (en) 2012-03-22
US20120142746A1 (en) 2012-06-07
IL225278A0 (en) 2013-06-27
MY168763A (en) 2018-12-04
AU2011301932A1 (en) 2013-05-02
EP3338777B1 (en) 2020-02-05
KR102104760B1 (ko) 2020-04-27
ES2613509T3 (es) 2017-05-24
IL225278A (en) 2015-11-30
HUE039090T2 (hu) 2018-12-28
HUE048725T2 (hu) 2020-09-28
CA2812197C (en) 2024-01-02
ES2781681T3 (es) 2020-09-04
IL225282A0 (en) 2013-06-27
KR20140005154A (ko) 2014-01-14
ZA201302291B (en) 2013-11-27
EP3053576B1 (en) 2018-05-16
DK3050564T3 (da) 2019-11-25
ES2737230T3 (es) 2020-01-10
KR20200044147A (ko) 2020-04-28
CN103200941B (zh) 2015-12-16
CY1121024T1 (el) 2019-12-11
BR112013006320A2 (pt) 2016-06-21
HUE049573T2 (hu) 2020-10-28
US20130289088A1 (en) 2013-10-31
AU2011301901B2 (en) 2016-02-11
CA2812195A1 (en) 2012-03-22
CL2013000735A1 (es) 2013-11-29
DK3078376T3 (da) 2019-06-24
EP2616066B1 (en) 2016-07-13
CA3079450A1 (en) 2012-03-22
EP3636263B1 (en) 2021-11-03
EP3659600A1 (en) 2020-06-03
PL3050563T3 (pl) 2018-12-31
TW201240661A (en) 2012-10-16
ZA201302193B (en) 2013-11-27
CA3077732A1 (en) 2012-03-22
ES2687420T3 (es) 2018-10-25
RU2013116405A (ru) 2014-10-27
SG188571A1 (en) 2013-04-30
HK1185539A1 (zh) 2014-02-21
US8492557B2 (en) 2013-07-23
MY161607A (en) 2017-04-28
PT3050564T (pt) 2019-12-11
EP3348264A1 (en) 2018-07-18
DK3348264T3 (da) 2020-03-23
EP2616067B1 (en) 2016-05-18
DK3636263T3 (da) 2022-01-10
KR101952457B1 (ko) 2019-02-26
CA2812191C (en) 2021-04-13
IL225281A0 (en) 2013-06-27
JP2013537237A (ja) 2013-09-30
US20120122945A1 (en) 2012-05-17
EP2616067A1 (en) 2013-07-24
BR112013006355A2 (pt) 2016-06-28
EP3636263A1 (en) 2020-04-15
US20120149746A1 (en) 2012-06-14
PT3050563T (pt) 2018-10-01
ZA201302194B (en) 2013-11-27
HK1257416A1 (zh) 2019-10-18
PT2616069T (pt) 2016-12-06
MX2013003004A (es) 2013-06-28
DK3338777T3 (da) 2020-04-20
US8653123B2 (en) 2014-02-18
US8853251B2 (en) 2014-10-07
CA2812191A1 (en) 2012-03-22
EP3050564B1 (en) 2019-09-04
EP3698789A1 (en) 2020-08-26
IL225280A0 (en) 2013-06-27
KR20190022895A (ko) 2019-03-06
MX2013003002A (es) 2013-06-28
ZA201302288B (en) 2013-11-27
PT3053576T (pt) 2018-10-08
AU2011301856A1 (en) 2013-05-02
CN103209694A (zh) 2013-07-17
KR102139905B1 (ko) 2020-07-31
HUE047476T2 (hu) 2020-04-28
SI3053576T1 (sl) 2018-11-30
ES2593612T3 (es) 2016-12-12
EP2616066A1 (en) 2013-07-24
SI3348264T1 (sl) 2020-07-31
US20130296394A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
HK1185541A1 (zh) 用於降低眼內壓的 -咪唑- -基 乙基 -甲基苯基 甲醇的酯前藥
ZA201005510B (en) Production of ethanol from methanol
HK1246204B (zh) 包含(3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基)甲醇的藥物組合物
HK1258392A1 (zh) 用於降低眼內壓的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前藥
IL226384A0 (en) Pharmaceutical preparations containing (3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl)methanol